Shelia M. Violette

Shelia M. Violette

Company: Q32 Bio

Job title: Co-Founder, Chief Scientific Officer & President of Research


The Potential for Tissue Targeted Complement Inhibition: Generation of a Novel Therapeutic Platform 9:30 am

Targeted delivery of negative regulatory proteins potently inhibits complement activation and injury in diseased tissue without systemic blockade Q32 Bio tissue targeted complement therapeutics biodistribute to diseased tissues and provide long-term durable tissue PK/PD and efficacy Q32 Bio tissue targeted complement therapeutics have the potential to be used for a wide range of disease indications…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.